Strut Health: Which Patient Profiles Should Avoid It and Is It Legit?

What Is Strut Health and How Does Its Model Work?

Strut Health is an async telehealth company dispensing compounded prescription medications for androgenic alopecia, acne, rosacea, erectile dysfunction, and related conditions. Patients fill out an online intake form, a licensed physician reviews it, and a compounding pharmacy ships the product directly.

The company does not operate its own pharmacy. It partners with 503A compounding pharmacies, which are regulated by state boards of pharmacy rather than by the FDA directly. The FDA oversees 503B outsourcing facilities under stricter standards, and the distinction matters for patients evaluating safety 1.

The 503A vs. 503B Distinction

A 503A pharmacy compounds on a patient-specific, prescription basis. It does not require FDA registration, does not undergo routine FDA facility inspections, and cannot sell to distributors or large institutional buyers 1. Strut's partner pharmacies appear to operate under 503A designation.

This is legal. However, the FDA has stated clearly that compounded drugs "are not FDA-approved" and that the agency "has not evaluated them for safety, efficacy, or quality before they are marketed" 1. Patients considering Strut should understand that the individual combinations Strut dispenses, such as finasteride plus minoxidil in a single topical formulation, have not gone through the same approval pathway as Propecia or Rogaine.

What Strut Prescribes Most Often

The platform's most common prescriptions include:

• Topical finasteride/minoxidil combinations for hair loss
• Oral finasteride for male-pattern baldness
• Tretinoin and azelaic acid formulas for acne and hyperpigmentation
• Oral or topical minoxidil for hair thinning
• Sildenafil and tadalafil for erectile dysfunction

Each of these active ingredients does have established evidence as a monotherapy. Finasteride 1 mg showed a 48% increase in hair count versus placebo in the key Phase III trial that supported FDA approval 2. Tretinoin's efficacy for photodamaged skin is supported by decades of dermatology data, including a 48-week randomized controlled trial published in the Archives of Dermatology showing statistically significant reduction in fine lines versus vehicle control 3. The issue is not the individual molecules. The issue is the compounded combinations and the absence of clinical oversight for the specific patient.

Patient Profiles That Should Not Use Strut

This is the most clinically important section of this review. Several groups face real contraindications or significant safety risks with Strut's most popular formulas.

Pregnant Women and Women of Childbearing Potential

Finasteride is FDA Pregnancy Category X. Even topical exposure may be absorbed systemically in quantities sufficient to cause abnormal development of male external genitalia in a male fetus 4. The FDA label for finasteride states: "Women who are pregnant or may potentially be pregnant should not handle crushed or broken PROSCAR tablets because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus" 4.

Strut's async model creates risk here. A patient might not fully disclose pregnancy status in a text-based intake form, and there is no real-time clinical conversation to catch that gap.

Tretinoin is also teratogenic. Oral retinoids carry well-documented teratogenicity risk, and while topical tretinoin has lower systemic absorption, the FDA label advises against use during pregnancy 5. Any woman who is pregnant, trying to conceive, or breastfeeding should avoid Strut's finasteride and tretinoin products entirely.

Men on Nitrate Medications

Sildenafil and tadalafil are absolutely contraindicated with nitrates. Co-administration can cause catastrophic hypotension. The FDA label for sildenafil states that "administration of VIAGRA to patients who are using any form of organic nitrate is contraindicated" 6. Patients on isosorbide mononitrate, nitroglycerin patches, or amyl nitrite should not use Strut's ED medications.

An async intake form is not a reliable screening tool for nitrate use, particularly in older men who may take these medications episodically.

Men on Alpha-Blockers

The same FDA label warns that combining PDE5 inhibitors with alpha-blockers (e.g., tamsulosin, doxazosin) may cause additive blood-pressure lowering and symptomatic hypotension 6. Men being treated for benign prostatic hyperplasia with alpha-blockers fall into this category.

Patients with Significant Hepatic Impairment

Finasteride is hepatically metabolized. The FDA prescribing information notes that finasteride has not been adequately studied in patients with hepatic insufficiency, and elevated exposure is possible in that population 4. Similarly, sildenafil AUC increases substantially in hepatic impairment. A starting dose of 25 mg is recommended in that context, a nuance an async prescriber may miss without current liver function data 6.

Patients with a History of Non-Arteritic Anterior Ischemic Optic Neuropathy

Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported post-marketing in patients using PDE5 inhibitors. The FDA label includes a specific warning advising these patients to stop the drug immediately and seek medical attention if sudden vision loss occurs 6. Patients with a prior episode of NAION in one eye are at elevated risk of recurrence in the second eye and should not use sildenafil or tadalafil through any channel, including Strut.

Patients with Post-Finasteride Syndrome or Known 5-alpha Reductase Sensitivity

Post-finasteride syndrome (PFS) refers to a cluster of persistent sexual, neurological, and endocrine adverse effects reported by some men after stopping finasteride. The Post-Finasteride Syndrome Foundation has documented hundreds of cases 7. A 2022 analysis in the Journal of Sexual Medicine found persistent sexual dysfunction in a meaningful subset of men who discontinued finasteride 8. Patients with a personal or family history of severe finasteride reactions should not use Strut's hair-loss products.

Patients Under 18

Strut's platform is not designed for pediatric patients. Finasteride is not approved for use in children. Sildenafil is approved in pediatric pulmonary arterial hypertension under a separate indication and specific dosing, not for ED. Any patient under 18 should not use Strut.

Is Strut Legit? Licensing, Accreditation, and Regulatory Standing

The short answer is: Strut operates within U.S. Law, but it carries important unverified credentials that patients should scrutinize.

Physician Licensing

Strut employs licensed U.S. Physicians and operates under the telehealth prescribing laws of the states where it practices. That is a legal baseline, not an endorsement of clinical quality.

LegitScript Certification

LegitScript is an independent verification service that monitors online pharmacies and telehealth platforms against DEA, FDA, and state pharmacy board standards. As of this article's review date, Strut does not appear to hold active LegitScript certification 9. LegitScript certification is voluntary but its absence means no third-party body has audited Strut's prescribing and dispensing practices.

BBB Standing

The Better Business Bureau does not currently show BBB accreditation for Strut Health. The BBB profile includes customer reviews that are mixed, with some users reporting shipping delays and difficulty reaching support 10. Lack of BBB accreditation alone is not disqualifying. However, patients researching "Strut complaints" should check the current BBB profile directly, as ratings change.

FDA Compounding Warning Letters

The FDA has issued hundreds of warning letters to 503A compounding pharmacies for sterility failures, misbranding, and unapproved drug components. While no public warning letter to Strut's specific partner pharmacy has been identified at time of writing, patients should know this risk exists across the compounding sector 11.

The table below summarizes Strut's regulatory standing across five verification axes. This framework was developed by the HealthRX medical team to give patients a consistent way to evaluate async compounding telehealth platforms.

| Verification Axis | Standard | Strut Status (as of review) | |---|---|---| | State medical board licensing | Required | Appears met | | LegitScript certification | Voluntary gold standard | Not certified | | BBB accreditation | Voluntary | Not accredited | | 503B FDA registration | Optional upgrade | Not applicable (503A model) | | NABP (.pharmacy domain or VIPPS) | Voluntary | Not verified |

Strut Complaints: What Real Users Report

Patient complaints about Strut cluster into a few recurring themes based on public reviews on the BBB and Reddit forums.

Shipping and Fulfillment Delays

Multiple reviewers describe waits of two to four weeks for initial shipments. Compounding pharmacies work to order, so this is not unusual in the sector. Patients who need medication reliably on a fixed schedule should account for this.

Difficulty Canceling Subscriptions

A subset of complaints describes challenges canceling automatic refill subscriptions. This is a common criticism of DTC health subscription models broadly, not unique to Strut. However, patients should review cancellation terms before subscribing.

Async Communication Gaps

Some users report that follow-up questions after receiving medication were handled slowly or via automated responses. For conditions like erectile dysfunction or hair loss, this may be tolerable. For patients who develop side effects, slow follow-up is a safety concern.

Product Efficacy Disputes

Some male users report no visible hair regrowth after three to six months of topical finasteride/minoxidil use. This is not necessarily a complaint about product quality: hair regrowth typically requires at least 12 months of consistent use to evaluate, per American Academy of Dermatology guidance 12. Patient expectations may be misaligned with the biology.

How Strut Compares to FDA-Approved Alternatives

Patients who fall into the contraindicated profiles above, or who want FDA-approved, individually tested products, have alternatives.

For Male Hair Loss

Finasteride 1 mg (Propecia) and minoxidil 5% solution (Rogaine) are both FDA-approved for androgenetic alopecia. The key finasteride trial (N=1,553 men, 5-year data) showed 48% increase in hair count versus placebo with 1 mg daily 2. These products have defined safety profiles, FDA-reviewed labeling, and post-market surveillance data.

For Erectile Dysfunction

Branded sildenafil (Viagra) and tadalafil (Cialis) are FDA-approved. Generic versions at identical doses are widely available and inexpensive. Several telehealth platforms (Roman, Hims, others) also prescribe FDA-approved generics rather than compounded versions. For patients on complex medication regimens, an in-person visit with a urologist or primary care physician adds a safety layer that async telehealth cannot provide.

For Acne and Skin

Tretinoin 0.025%, 0.05%, and 0.1% in cream and gel formulations are FDA-approved and available through conventional dermatology practices. Azelaic acid 15% gel (Finacea) and 20% cream (Azelex) carry individual FDA approval 13. For patients with moderate-to-severe acne, the American Academy of Dermatology's 2016 guidelines recommend systematic evaluation including assessment of antibiotic resistance patterns, something not possible in an async intake form 14.

Clinical Bottom Line: When Strut Is and Is Not Appropriate

Strut may be a reasonable option for healthy, non-pregnant adults with straightforward androgenic alopecia, mild acne, or ED who have no cardiac, hepatic, or medication contraindications, who have disclosed their full medication list accurately in the intake form, and who understand they are receiving compounded rather than FDA-approved products.

Strut is not appropriate for:

• Pregnant women or women who may become pregnant (finasteride, tretinoin)
• Men on any form of nitrate medication (sildenafil, tadalafil)
• Men on alpha-blockers for BPH (sildenafil, tadalafil)
• Patients with significant hepatic impairment (finasteride, sildenafil)
• Patients with prior NAION (sildenafil, tadalafil)
• Anyone under 18
• Patients who prefer FDA-approved products with individual approval documentation

The FDA's guidance on compounding states that "patients and prescribers should be aware that compounded drugs have not been approved by FDA" and that this represents a meaningful difference in the quality-assurance chain 1. For complex cases, a board-certified dermatologist, urologist, or endocrinologist in person remains the safest pathway.